Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Needham & Company LLC

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $44.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 258.16% from the stock’s current price.

Several other research analysts have also issued reports on LYEL. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. Finally, Citizens Jmp assumed coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock traded up $0.32 during midday trading on Monday, hitting $12.29. 33,065 shares of the company’s stock were exchanged, compared to its average volume of 96,139. Lyell Immunopharma has a 52-week low of $8.46 and a 52-week high of $45.00. The stock has a 50-day moving average price of $19.87 and a two-hundred day moving average price of $23.47. The company has a market cap of $286.61 million, a P/E ratio of -0.89 and a beta of -0.09.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, sell-side analysts expect that Lyell Immunopharma will post -7.87 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its position in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares during the period. Marshall Wace LLP purchased a new position in shares of Lyell Immunopharma during the second quarter valued at approximately $94,000. Bridgeway Capital Management LLC purchased a new stake in shares of Lyell Immunopharma in the second quarter valued at approximately $159,000. BBR Partners LLC purchased a new stake in shares of Lyell Immunopharma in the fourth quarter valued at approximately $210,000. Finally, Walleye Capital LLC purchased a new stake in shares of Lyell Immunopharma in the second quarter valued at approximately $258,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.